Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113.
(412.73 KB)
. 
Visual or automated dipstick testing for proteinuria in pregnancy?. Pregnancy Hypertens. 2017;7:50-53.
(234.13 KB)
. 
Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. J Obstet Gynaecol Can. 2017;39(9):728-733.e3.
(176.34 KB)
. 
Utilization of maternal health care services and their determinants in Karnataka State, India. Reprod Health. 2016;13 Suppl 1:37.
(941.52 KB)
. 
Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.
(269.78 KB)
. 
The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918.
(304.95 KB)
. 
Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. JMIR Mhealth Uhealth. 2015;3(2):e37.
(831.85 KB)
. 
Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877.
(1021.64 KB)
. 
Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152.
(834.74 KB)
. 
Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50.
(887.01 KB)
. 
SOCIETAL PERSPECTIVE ON COST DRIVERS FOR HEALTH TECHNOLOGY ASSESSMENT IN SINDH, PAKISTAN. Int J Technol Assess Health Care. 2017;33(2):192-198.
(266.82 KB)
. 
Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. Int J Health Geogr. 2017;16(1):1.
(9.27 MB)
. 
A scoping review of geographic information systems in maternal health. Int J Gynaecol Obstet. 2016;134(1):13-7.
(497.99 KB)
. 
The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.
(370.8 KB)
. 
A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589.
(353.97 KB)
. 
Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932-42.
(529.57 KB)
. 
Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4.
(189.28 KB)
. 
A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.
(336.66 KB)
. 
Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1
. A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238.
(925.17 KB)
. 
Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.
(447.63 KB)
. 
Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.
(389.82 KB)
. 
Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10169):330-339.
(10.3 MB)
. 
PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.
(183.96 KB)
. 
Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.
(322.96 KB)
. 
Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48.
(309.47 KB)
. 
Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.
(486.35 KB)
. 
Pre-eclampsia. Lancet. 2010;376(9741):631-44.
(809.94 KB)
. 
Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC Med. 2017;15(1):68.
(932.74 KB)
. 
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.
(201.46 KB)
. 
Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.
(501.41 KB)
. 
Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.
(317.15 KB)
. 
Potential for task-sharing to Lady Health Workers for identification and emergency management of pre-eclampsia at community level in Pakistan. Reprod Health. 2016;13(Suppl 2):107.
(286.51 KB)
. 
Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open. 2019;9(2):e024042.
(2.94 MB)
. 
Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.
(986.49 KB)
. 
Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.
(475.29 KB)
. 
PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.
(292.91 KB)
. 
PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.
(292.91 KB)
. 
The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.
(233.18 KB)
. 
Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.
(529.81 KB)
. . 
Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.
(383.37 KB)
. 
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220.
(158.15 KB)
. 
Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57.
(910.16 KB)
. 
Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.
(662.6 KB)
. 
Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6.
(660.26 KB)
. 
Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.
(2.12 MB)
. 
Massive Urinary Protein Excretion Associated with Greater Neonatal Risk in Preeclampsia. AJP Rep. 2017;7(1):e49-e58.
(184.83 KB)
. 
Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can. 2016;38(10):936-944.e3.
(667.48 KB)
. 
Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.
(1.42 MB)
. 